Investors

Developing transformative therapies targeting cancer

Founded 20 years ago, Seattle Genetics was built on a foundation of scientific innovation, rigorous research and drug development practices, as well as a passion for helping patients. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer has resulted in an approved drug for multiple indications and a robust pipeline of innovative programs in clinical development for a range of hematologic and solid tumors.

Recent News
Seattle Genetics Reports Second Quarter 2019 Financial Results More
Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer More
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019 More
Events


Copyright West LLC. Minimum 15 minutes delayed.